Participated · Series C · Nov 2025

Aspen Neuroscience is pioneering personalized regenerative medicine by converting a patient’s own skin cells into induced pluripotent stem cells and then into dopaminergic neuronal precursor cells to treat neurodegenerative diseases. Its lead candidate, ANPD001, is the most advanced autologous cell therapy in the U.S. for moderate to advanced Parkinson’s disease and has received FDA Fast Track designation. The company’s proprietary manufacturing platform integrates machine-learning-based genomic testing for rigorous quality control and scalability, and it includes a precision MRI-guided delivery device for minimally invasive transplantation. Recent clinical progress includes initiation of Cohort 3 in a Phase 1/2a trial, with earlier cohorts showing favorable safety and clinician- and patient-reported improvements without the need for immunosuppression. Aspen plans to expand its pipeline to additional neurological indications while scaling manufacturing to meet future commercial demand. Headquartered in San Diego, the private company has raised more than $340 million to date, including an $8 million grant from the California Institute for Regenerative Medicine.

Participated · Series B · May 2023

Ensoma is a Boston-based biotechnology company focused on engineering hematopoietic stem cells directly inside the body to create durable genetic medicines for genetic diseases, immune disorders, and cancer. Its platform uses high-capacity virus-like particles (VLPs) that selectively target HSCs and can deliver up to 35 kb of genetic cargo, enabling single-base edits through large multi-gene insertions. The company combines these VLPs with proprietary base-editing and gene-integration systems, aiming for one-time intravenous administration. Proceeds from its latest financing will fund a Phase 1/2 clinical trial of lead candidate EN-374 for X-linked chronic granulomatous disease and support platform expansion into immuno-oncology and sickle cell programs. Ensoma’s strategy centers on creating off-the-shelf, non-myeloablative treatments that avoid the complexity and cost of ex vivo cell processing. The firm’s board now includes a Gilead appointee following the strategic investment. No financial metrics or commercial revenues have been disclosed to date.

Participated · Equity · Nov 2021

Shoreline Biosciences is developing intelligently designed, off-the-shelf induced pluripotent stem cell (iPSC)-derived NK and macrophage cellular immunotherapies. The company focuses on standardized, targeted cell products including next-generation, more persistent iPSC-derived NK cells and macrophage-cell therapies. Shoreline is advancing proprietary iPSC differentiation methods, genetic reprogramming of disease-relevant pathways, and plans to create NK-specific CARs, switchable CAR-NK engagers, and macrophage-specific CARs. It targets both hematologic malignancies and solid tumors and has established strategic partnerships with Kite (a Gilead Company) and BeiGene. Shoreline also reports contract development and manufacturing organization (CDMO) partnerships to support manufacturing. The company is headquartered in San Diego, CA and is well-capitalized to continue pipeline advancement. Shoreline Biosciences is developing intelligently designed allogeneic, off-the-shelf natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC). The company focuses on standardized and targeted NK- and macrophage-based cell therapies for cancer and other serious diseases. It plans to use new funding to accelerate advancement of its proprietary iPSC platform and next-generation NK and macrophage cell therapy programs. Research efforts supported by the financing include work to create potent and persistent NK cell-specific chimeric antigen receptors (CARs), switchable CAR-NK cell engagers, and macrophage-specific CARs. Shoreline has entered a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego to secure GMP manufacturing of its cell therapy products. The company was co-founded by Dan Kaufman, M.D., Ph.D., along with Steven Holtzman, William Sandborn, M.D., and Kleanthis G. Xanthopoulos, Ph.D.

Participated · Series A · Feb 2021

Orna Therapeutics was created in 2019 by MPM and BioImpact Capital based on MIT research and is developing circular RNA (oRNA) platforms for vaccines and therapeutics. Its circular RNA approach is designed to offer greater stability than linear mRNA and to produce larger quantities of therapeutic protein in vivo. Orna also develops proprietary lipid nanoparticles and has a joint venture with ReNAgade Therapeutics for RNA delivery. The company’s pipeline targets infectious diseases, oncology, and other illnesses, and the collaboration announced covers multiple programs across vaccines and cancer. Orna plans to accelerate development through a landmark collaboration and expects to derive royalties on approved products. Financially, Orna announced a $221 million Series B at a valuation above $1.5 billion and will receive $150 million upfront under the collaboration plus up to $3.5 billion in development, regulatory, and sales milestones. Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics. Its proprietary platform combines molecular design and delivery technologies to create oRNAs that drive protein expression. The company aims to treat a wide range of diseases including cancer, autoimmune, and genetic disorders. Orna was founded on research from MIT and was seeded and incubated by MPM Capital; founders include Robert Alex Wesselhoeft, Raffaella Squilloni, and Professor Dan Anderson. Thomas M. Barnes, Ph.D., serves as CEO and the company is supported by an experienced board of directors and scientific advisors. Orna completed an $80M Series A financing to advance its oRNA platform.

Participated · Series C · Aug 2019

HiFiBiO Therapeutics is a multinational biotherapeutics company that combines single-cell profiling, deep biological expertise, and data intelligence (DIS™) to discover and develop antibody drugs. Its core focus is differentiated antibody therapeutics for oncology and autoimmune disorders, with multiple discovery-stage programs and clinical candidates. The company will use proceeds from its oversubscribed $75M Series D to advance two lead oncology antibodies—HFB200301 (anti‑TNFR2) and HFB301001 (second‑generation anti‑OX40)—into Phase I trials and to continue discovery and clinical development. HiFiBiO also highlighted prior progress including rapid development of HFB30132A, a SARS‑CoV‑2 neutralizing antibody, into a Phase I trial (NCT04590430) and the launch of IND‑enabling studies and biomanufacturing for multiple antibodies. The company intends to validate its DIS™ approach and biomarker hypotheses in the clinic to enhance the probability of trial success for current and future programs. HiFiBiO operates laboratories across Cambridge, Mass.; Paris; Shanghai; Hong Kong; and Hangzhou, reflecting a global footprint. HiFiBiO Therapeutics operates a proprietary single-cell analytics platform (including CelliGO™) and Drug Intelligent Science (DIS™) to enable deep immune profiling and antibody discovery. The company integrates biological expertise with comprehensive single-cell technologies to identify precise patient subsets and novel biomarkers. HiFiBiO aims to advance multiple antibody drug candidates into clinical trials and accelerate pipeline development. It plans to use platform expansion to increase discovery throughput while reducing time and costs. The company has announced collaborations, an acquisition, a joint venture, and a Nature Genetics publication that demonstrate scientific and strategic progress. HiFiBiO maintains laboratories across Cambridge, Mass., Paris, France, and Shanghai, China. HiFiBiO Therapeutics develops antibody drugs by integrating deep biological expertise with single-cell profiling technologies and its proprietary single-B-cell functional antibody discovery CelliGOTM platform. The company is focused on advancing a pipeline of antibody therapeutics for cancer and autoimmune diseases and is establishing strategic partnerships with pharmaceutical and biotechnology companies to drive that pipeline. HiFiBiO operates more than 50 full-time employees across three facilities in the USA, France and China, with laboratories in Cambridge, MA and Hangzhou, China located within Nest.Bio Ventures incubator facilities. Liang Schweizer, PhD, serves as President and CEO, supported by a leadership team including Jeff He (COO), Colin Brenan, PhD (CCO) and Fred Dom (CFO). Financially, the company completed a $37.5M Series B financing in 2018 to support its discovery and development efforts. The company positions its proprietary platform and strategic partnerships as central to advancing its therapeutic pipeline.